Arsenic Trioxide Enhances Radiation Response of 9L Glioma in the Rat Brain

Radiation Research

Volumn 160, Issue 6, 2003, Pages 662-666

  Kim, Jae Ho ^a,b   Lew, Young S ^a   Kolozsvary, Andrew ^a   Ryu, Samuel ^a   Brown, Stephen L ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; FLUORESCEIN ISOTHIOCYANATE DEXTRAN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; BRAIN; CONTROLLED STUDY; FOLLOW UP; GLIOMA; HISTOPATHOLOGY; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIATION RESPONSE; RAT; SURVIVAL;

ANIMALS; ANTINEOPLASTIC AGENTS; ARSENICALS; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; GLIOMA; MAGNETIC RESONANCE IMAGING; MALE; OXIDES; RATS; RATS, INBRED F344;

ANIMALIA;

EID: 0348014917     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.1667/RR3069     Document Type: Article

References (25)

1. W. H. Miller, Jr., Molecular targets of arsenic trioxide in malignant cells. Oncologist 7, 14-19 (2002).
2. S. L. Soignet, S. R. Frankel, D. Douer, M. S. Tallman, H. Kantarjian, E. Calleja, R. M. Stone, M. Kalaycio, D. A. Scheinberg and R. P. Warrell, Jr., United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J. Clin. Oncol. 19, 3852-3860 (2001).
3. J. Zhu, Z. Chen, V. Lallemand-Breitenbach and H. de The, How acute promyelocytic leukaemia revived arsenic. Nat. Rev. Cancer 2, 705-713 (2002).
4. Y. S. Lew, S. L. Brown, R. J. Griffin, C. W. Song and J. H. Kim, Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shut down. Cancer Res. 59, 6033-6037 (1999).
5. Y. S. Lew, S. L. Brown, A. Kolozsvary and J. H. Kim, Improved tumor response with combined radiation and vascular targeting agent, arsenic trioxide. Cancer Res. 62, 4202-4205 (2002).
6. S. A. Hill, L. E. Sampson and D. J. Chaplin, Anti-vascular approaches to solid tumor therapy: Evaluation of vinblastine and flavone acetic acid. Int. J. Cancer 63, 119-123 (1995).
7. M. R. Horsman, M. Nordsmark, M. Hoyer and J. Overgaard, Direct evidence that hydralazine can induce hypoxia in both transplanted and spontaneous murine tumors. Br. J. Cancer 72, 1474-1478 (1995).
8. B. C. Baugley, K. H. Holdaway and L. L. Thomsen, Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicines. Evidence for a vascular mechanism. Eur. J. Cancer 27, 482-487 (1991).
9. K. T. Wheeler and K. Kaufman, Efficacy of continuous treatment with radiation in a rat brain-tumor model. J. Neurosurg. 55, 52-54 (1981).
10. J. H. Kim, M. S. Khil, A. Kolozsvary, J. A. Gutierrez and S. L. Brown, Fractionated radiosurgery for 9L gliosarcoma in the rat brain. Int. J. Radiat. Oncol. Biol. Phys. 45, 1035-1040 (1999).
11. S. L. Brown, J. R. Ewing, A. Kolozsvary, S. Butt, Y. Cao and J. H. Kim, Magnetic resonance imaging of perfusion in rat cerebral 9L tumor after nicotinamide administration. Int. J. Radiat. Oncol. Biol. Phys. 43, 627-633 (1999).
12. S. L. Brown, J. R. Ewing, T. Nagaraja, P. S. Swerdlow, Y. Cao, J. D. Fenstermacher and J. H. Kim, Imaging tumor vasculature using sickle red blood cells. Magn. Reson. Med., in press.
13. T. L. Chenevert, L. D. Stegman, J. M. Taylor, P. L. Robertson, H. S. Greenberg, A. Rehemtulla and B. D. Ross, Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J. Natl. Cancer Inst. 92, 2029-2036 (2000).
14. S. Ryu, S. L. Brown, A. Kolozsvary, J. R. Ewing and J. H. Kim, Non-invasive detection of radiation-induced optic neuropathy by manganese-enhanced MRI. Radiat. Res. 157, 500-505 (2002).
15. E. L. Kaplan and P. Meier, Non-parametric estimation from incomplete observations. J. Am. Stat. Assoc. 53, 457-481 (1958).
16. N. Mantel, Evaluation of survival data and two new ranks order statistics arising in its consideration. Cancer Chemother. Rep. 50, 163-170 (1966).
17. W. R. Wilson, A. E. Li, D. S. M. Cowan and B. G. Sim, Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone 4-acetic acid. Int. J. Radiat. Oncol. Biol. Phys. 42, 905-908 (1998).
18. R. Murahata, D. W. Siemann, J. Overgaard and M. R. Horsman, Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors. Radiother. Oncol. 60, 155-161 (2001).
19. D. W. Siemann and A. M. Rojiani, Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int. J. Radiat. Oncol. Biol. Phys. 53, 164-171 (2002).
20. D. E. Hallahan, M. A. Beckett, D. Kufe and R. R. Weichselbaum, The interaction between recombinant human tumor necrosis factor and radiation in 13 human tumor cell lines. Int. J. Radiat. Oncol. Biol. Phys. 19, 69-74 (1990).
21. K. Kimura, C. Bowen, S. Spiegel and E. P. Gelmann, Tumor necrosis factor-alpha sensitizes prostate cancer cells to gamma-irradiation-induced apoptosis. Cancer Res. 59, 1606-1614 (1999).
22. G. M. Tozer, C. Kanthou, C. S. Parkins and S. A. Hill, The biology of the combretastatins as tumour vascular targeting agents. Int. J. Exp. Pathol. 83, 21-38 (2002).
23. R. A. Brekken and P. E. Thorpe, Vascular endothelial growth factor and vascular targeting of solid tumors. Anticancer Res. 21, 4221-4229 (2001).
24. D. W. Siemann, K. H. Warrington and M. R. Horsman, Targeting tumor blood vessels: An adjuvant strategy for radiation therapy. Radiother. Oncol. 57, 5-12 (2000).
25. D. W. Siemann, E. Mercer, S. E. Lepler and A. M. Rojiani, Vascular targeting agents enhance chemotherapeutic agents in solid tumor therapy. Int. J. Cancer 99, 1-6 (2002).